Clinical Trials
39 trialsNCT00814021 2026-04-15
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
Institut Claudius Regaud
Phase 2 Completed
NCT03091192 2026-04-14
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
Phase 3 Active not recruiting
NCT06726421 2026-01-15
STROKER
Sun Yat-sen University
Phase 3 Recruiting
NCT02684006 2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3 Completed
NCT01164228 2023-06-15
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT03729245 2023-04-11
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
Nektar Therapeutics
Phase 3 Terminated
NCT03035630 2022-02-15
Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT02689167 2021-11-29
SURF
Centre Hospitalier Universitaire de Besancon
Phase 2 Unknown
NCT01185366 2021-04-28
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00853125 2021-04-27
Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT00541008 2021-02-21
Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer
UNICANCER
Phase 2 Completed
NCT02060370 2020-02-27
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03571438 2020-01-18
COMBOREIN
University Hospital, Grenoble
Phase NA Unknown
NCT03323710 2019-01-09
Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma
Military Institute od Medicine National Research Institute
Phase 2 Withdrawn
NCT00375674 2018-09-21
S-TRAC
Pfizer
Phase 3 Completed
NCT02386111 2018-07-26
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Celldex Therapeutics
Phase 1 Terminated
NCT01582672 2018-06-14
ADAPT
Argos Therapeutics
Phase 3 Terminated
NCT01108445 2018-01-16
ASPEN
Duke University
Phase 2 Completed
NCT00537056 2017-06-14
Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
Stanford University
Phase NA Completed
NCT00425386 2017-05-03
Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer
OHSU Knight Cancer Institute
Phase 2 Completed
NCT02446795 2017-01-18
QUASAR
Consorzio Oncotech
Phase 1/2 Unknown
NCT00943839 2016-11-10
Sunitinib Malate in Treating Patients With Kidney Cancer
Centre Antoine Lacassagne
Phase NA Completed
NCT00903175 2016-11-08
RECORD-3
Novartis
Phase 2 Completed
NCT00465179 2016-06-07
Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02688491 2016-02-25
A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment
First Affiliated Hospital, Sun Yat-Sen University
Phase NA Not yet recruiting
NCT00462982 2015-12-30
Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00459875 2015-11-26
Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01122615 2015-11-18
Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00747305 2015-10-22
Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery
Medical University of South Carolina
Phase 1 Terminated
NCT00849186 2015-02-06
Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer
Roswell Park Cancer Institute
Phase NA Completed
NCT00459979 2014-03-07
Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00399152 2014-02-19
Perifosine + Sunitinib Malate for Patients With Advanced Cancers
AEterna Zentaris
Phase 1 Completed
NCT00717587 2014-01-10
Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00626509 2013-08-12
Sunitinib Before or After Surgery in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01024205 2013-08-12
Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00678119 2013-07-15
Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment
Argos Therapeutics
Phase 2 Completed
NCT01070186 2012-07-31
Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT00422344 2010-02-26
A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00421512 2008-11-11
A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients
Memorial Sloan Kettering Cancer Center
Phase 1 Completed